Last Updated: November 16, 2026

Details for Patent: 8,669,273

« Back to Dashboard


Which drugs does patent 8,669,273 protect, and when does it expire?

Patent 8,669,273 protects NERLYNX and is included in one NDA.

This patent has thirty-nine patent family members in twenty-five countries.

Summary for Patent: 8,669,273
Title:Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Abstract:A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
Inventor(s):Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich
Assignee: Wyeth LLC
Application Number:US12/534,895
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent landscape, scope, and claims:

US Patent 8,669,273: Neratinib and Capecitabine Patent Scope, Expiration, and Patent Landscape

US Patent 8,669,273 protects specific combination-treatment methods using neratinib and capecitabine for ErbB-2-positive metastatic or locally advanced breast cancer. Its strongest commercial coverage is the regimen in claim 23: daily oral neratinib during a 21-day cycle combined with capecitabine on days 1 through 14. The patent does not broadly cover neratinib, capecitabine, or all breast-cancer treatment. It covers a defined combination, patient population, dosing framework, and asserted synergistic effect.

The patent is assigned to Wyeth, now within Pfizer’s corporate patent history. Puma Biotechnology obtained rights to develop and commercialize neratinib from Pfizer. The patent’s projected ordinary expiration is in 2029, subject to the patent’s recorded term adjustment and any applicable terminal disclaimer. It is not the principal composition-of-matter patent for neratinib.

What does US Patent 8,669,273 cover?

The patent covers methods that satisfy all of the following core limitations:

Core limitation Scope
Disease ErbB-2-positive metastatic breast cancer
Additional disease coverage Locally advanced breast cancer under dependent claim 2
Active agents Neratinib and capecitabine
Therapeutic relationship The agents must act synergistically
Route Oral administration is expressly claimed in dependent claim 4
Scheduling Concurrent, sequential, simultaneous, ordered, or specified temporal administration
Capecitabine dose About 1,250 mg to about 3,000 mg daily
Neratinib dose About 20 mg to about 240 mg daily in claim 21; at least 40 mg, 120 mg, or 240 mg under claims 11 to 13
Cycle structure Twenty-one-day cycle, with capecitabine on days 1 through 14 under claim 23
Treatment duration Capecitabine for three to six cycles, or discontinuation after about 24 weeks under dependent claims
Patient Human subject under claim 22

The independent claims are method-of-treatment claims, not product claims. A party would generally need to practice the claimed combination regimen to create infringement risk. Selling neratinib alone, selling capecitabine alone, or treating a cancer that does not satisfy the ErbB-2-positive limitation would not, by itself, practice the central claimed method.

How do claims 1 and 23 differ?

Claim 1 is broad in therapeutic concept but contains several important limitations. Claim 23 is narrower in dosing and scheduling but may be commercially more relevant because it maps more closely to a recognizable treatment protocol.

Feature Claim 1 Claim 23
Disease ErbB-2-positive metastatic breast cancer ErbB-2-positive metastatic breast cancer
Agents Neratinib plus capecitabine Neratinib plus capecitabine
Synergy limitation Yes Yes
Oral route Not required by the claim Required
Cycle length Not specified Twenty-one days
Neratinib schedule Not specified At least one unit dose daily starting day 1
Capecitabine schedule Not specified At least one unit dose on days 1 through 14
Treatment order Broad alternatives in dependent claims Defined cycle regimen
Commercial relevance Broad combination concept Specific combination protocol

Claim 23 is not merely a claim to co-administration. It requires the particular 21-day cycle and the day 1-to-day 14 capecitabine schedule. A generic manufacturer or clinical operator would need to assess whether its proposed labeling, instructions, or foreseeable use would induce practice of those limitations.

What is the scope of the synergy limitation?

The phrase “wherein neratinib and capecitabine act synergistically” is a material limitation in claims 1 and 23. It narrows the claims beyond simple additive combination therapy.

The patent’s technical theory is that inhibition of ErbB-family signaling by neratinib can enhance the antitumor activity of capecitabine or its active metabolite, 5-fluorouracil. The asserted synergy is relevant to patentability because it supports an argument that the claimed combination produced an unexpected therapeutic result.

The limitation also creates enforcement and validity issues:

  1. The patent holder would need to establish that the accused regimen produces the claimed synergistic effect.
  2. The relevant evidence may include clinical data, tumor-response data, combination-index analysis, preclinical models, or the patent specification’s experimental results.
  3. A defendant could challenge the term as indefinite if the patent does not provide an objective test for determining when the combination is synergistic.
  4. A defendant could challenge enablement or written description if the specification does not support the full range of claimed doses, schedules, cancer subtypes, and treatment sequences.

The synergy limitation is therefore both a scope restriction and a potential litigation pressure point. It may make the claims harder to invalidate on anticipation, while also making infringement proof more demanding.

What formulations and dosage forms are protected?

US 8,669,273 is not principally a formulation patent. It does not claim a particular tablet composition, capsule architecture, excipient system, coating, particle size, salt, polymorph, or fixed-dose combination product.

The patent protects administration of the active agents. Relevant covered variables include:

  • Oral versus non-oral administration, where the dependent claims apply.
  • Unit dosing of neratinib and capecitabine.
  • Daily or at-least-daily neratinib administration.
  • Capecitabine dosing between approximately 1,250 mg and 3,000 mg daily.
  • Neratinib dosing from approximately 20 mg to 240 mg daily.
  • Simultaneous, concurrent, sequential, or ordered dosing.

A separate product could therefore raise different patent questions for:

  • Neratinib tablets.
  • Capecitabine tablets.
  • A fixed-dose neratinib-capecitabine product.
  • Modified-release or gastroprotective formulations.
  • Combination packaging.
  • Manufacturing processes for neratinib or capecitabine.

A product or formulation patent would need to be analyzed separately from the treatment-method claims in US 8,669,273.

When does US Patent 8,669,273 expire?

The patent was issued on March 11, 2014. Its ordinary projected patent-term expiration is approximately January 2029, based on the underlying US/PCT filing history. The precise terminal date must be taken from the USPTO patent record because patent-term adjustment can change the expiration date.

Event Date or status
Patent US 8,669,273
Title Methods for treating cancer using neratinib and capecitabine
Issue date March 11, 2014
Patent type Method of treatment
Expected term basis Twenty years from the relevant nonprovisional/PCT filing date
Projected ordinary expiration Approximately January 2029
Patent-term adjustment Must be confirmed from USPTO records
Patent-term extension No established basis for assuming one
Regulatory exclusivity Separate from patent term

The patent’s expiration is not the same as the expiration of every neratinib patent. Neratinib may be protected by composition, formulation, manufacturing, crystalline-form, or other method-of-use patents with different dates.

What is the Orange Book status of US 8,669,273?

US 8,669,273 should not be treated as an automatic Orange Book barrier merely because it concerns neratinib. Orange Book listing is tied to patents that claim the approved drug substance, drug product, or an FDA-approved method of use.

Nerlynx is approved for extended adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. The patented method in US 8,669,273 concerns neratinib plus capecitabine for metastatic or locally advanced ErbB-2-positive breast cancer. That combination is not the principal FDA-approved Nerlynx indication.

Accordingly:

  • The patent is not the composition-of-matter patent for neratinib.
  • Its metastatic combination indication does not automatically qualify for Orange Book listing.
  • A listing, if any, must be verified against the current FDA Orange Book and Drugs@FDA patent records.
  • An Orange Book listing would affect ANDA certification and potential Paragraph IV litigation.
  • Absence from the Orange Book would not eliminate all infringement risk, because a patent owner could pursue a separate method-of-treatment claim under 35 U.S.C. § 271.

What FDA exclusivity protects neratinib?

Neratinib received FDA approval for Nerlynx in July 2017. The approved use was extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab-based adjuvant therapy, not the neratinib-capecitabine metastatic regimen claimed in US 8,669,273.[2]

FDA regulatory exclusivity and patent exclusivity operate separately:

Protection Relevance
New chemical entity exclusivity Applies to the approved active ingredient and blocks certain ANDA filings for the statutory period
Orphan-drug exclusivity Depends on the approved indication and orphan designation
Pediatric exclusivity Can add six months if granted
Patent term Depends on each patent’s filing history and term adjustment
Method-of-use exclusivity Depends on the approved labeling and listed patent claims

The approval of Nerlynx does not establish FDA approval of the patented neratinib-capecitabine regimen. A generic applicant could seek approval for a different indication or use a section viii statement to carve out protected methods if the statutory and labeling requirements are met.

Are Paragraph IV challenges likely for this patent?

A Paragraph IV challenge is relevant only if US 8,669,273 is listed in the Orange Book for the relevant reference-listed drug. If it is not listed, an ANDA applicant would not ordinarily certify against it through the standard Orange Book mechanism.

Potential challenge theories include:

Lack of anticipation

A challenger would search for earlier disclosures of:

  • Neratinib plus capecitabine.
  • HER2-positive metastatic breast cancer treatment.
  • The claimed dosing ranges.
  • Twenty-one-day cycles.
  • Capecitabine on days 1 through 14.
  • Synergistic activity.

A prior-art reference would generally need to disclose all elements of the relevant claim, either expressly or inherently.

Obviousness

The strongest obviousness theory would combine known neratinib activity in HER2-positive disease with known capecitabine use in metastatic breast cancer. The patent holder would respond that the particular combination, dosing, schedule, and synergistic effect were not predictable.

Indefiniteness

The “synergistically” limitation may be challenged if the patent fails to identify an objective standard for determining synergy. The strength of this challenge depends on the specification, prosecution history, expert evidence, and claim construction.

Enablement and written description

Claims 1 and 23 cover a range of disease states, doses, sequencing arrangements, and treatment durations. A challenger could argue that the disclosure does not enable the full breadth of those combinations.

No publicly established Paragraph IV litigation against US 8,669,273 is identified here. Generic litigation concerning other neratinib patents would not establish a challenge to this patent.

Which companies are relevant to the patent landscape?

The principal commercial parties are:

Company Role
Wyeth/Pfizer Original development and patent ownership history
Puma Biotechnology Exclusive commercial development and marketing rights for neratinib
Roche/Genentech Developer and marketer of capecitabine’s branded product, Xeloda
Generic manufacturers Potential ANDA sponsors for neratinib or capecitabine
FDA Approval, labeling, exclusivity, and Orange Book administration
USPTO Patent issuance, term adjustment, and prosecution records

Capecitabine is a mature small-molecule product with broad generic availability. It is not the principal commercial barrier in this combination. The commercial protection is concentrated in neratinib access, approved labeling, clinical positioning, and the remaining patent estate.

How strong is the patent estate for the neratinib-capecitabine combination?

US 8,669,273 has moderate strategic value but limited standalone breadth.

Strengths

  • It covers a defined combination of two orally administered anticancer agents.
  • It claims metastatic ErbB-2-positive disease, a commercially meaningful population.
  • Claim 23 captures a clinically recognizable 21-day regimen.
  • The synergy limitation can support nonobviousness.
  • The patent remains relevant through approximately 2029, subject to the official term calculation.

Weaknesses

  • It is a method patent rather than a composition patent.
  • The combination is not the principal FDA-approved Nerlynx use.
  • The synergy requirement may complicate infringement proof.
  • The claims do not broadly cover neratinib monotherapy.
  • The patent does not create a formulation or manufacturing barrier.
  • Generic capecitabine is readily available.
  • A competitor may avoid literal infringement through a different indication, schedule, dose, or label.

The strongest practical value is claim 23 when a competitor’s clinical protocol or labeling mirrors the claimed cycle. The weakest position is against a product that does not promote the combination and whose foreseeable use does not follow the claimed regimen.

What generic launch risks exist?

A generic neratinib launch would create several distinct risk categories:

  1. Patent risk from composition or formulation patents covering neratinib.
  2. Method-of-use risk from patents directed to approved or unapproved treatment regimens.
  3. Induced-infringement risk if the proposed labeling encourages the claimed neratinib-capecitabine combination.
  4. Regulatory risk if the FDA-approved label cannot be sufficiently carved out.
  5. Commercial risk from limited demand for a metastatic combination that is not the principal Nerlynx indication.
  6. Clinical substitution risk because capecitabine is already generic and can be prescribed separately.

A “skinny label” strategy could reduce risk if protected combination use is omitted from the proposed labeling and the remaining label does not encourage that use. It would not eliminate liability if the patent holder proves that the manufacturer actively encouraged the patented combination through marketing, instructions, or other conduct.

What patent litigation and settlement issues matter?

The key litigation questions are:

  • Whether US 8,669,273 is listed for the reference product.
  • Whether any ANDA applicant has certified against it.
  • Whether the patent holder has filed an infringement action within the statutory deadline.
  • Whether the claims survive claim construction.
  • Whether the court treats “synergistically” as an objective, enforceable limitation.
  • Whether a settlement permits an early generic launch.
  • Whether any settlement includes a payment, license, authorized generic, or launch-date provision.

A settlement involving a different neratinib patent does not necessarily resolve rights under US 8,669,273. Each patent must be included expressly or addressed through a sufficiently broad license.

What geographic coverage does the patent provide?

US 8,669,273 provides rights only in the United States. Parallel patent families may exist in Europe, Canada, Japan, Australia, and other jurisdictions, but foreign rights depend on national grants, claim amendments, opposition proceedings, and local expiration dates.

A US patent does not block:

  • Manufacture and sale outside the United States.
  • Foreign clinical use.
  • Importation into the United States if the imported product is used in a way that practices the patented method.
  • Foreign sales that do not create US infringement.

For global licensing or launch planning, the US patent must be mapped against each foreign family member and local regulatory indication.

Key Takeaways

  • US 8,669,273 claims treating ErbB-2-positive metastatic or locally advanced breast cancer with neratinib plus capecitabine.
  • Claim 23 is the most commercially specific claim because it requires daily oral neratinib and capecitabine on days 1 through 14 of a 21-day cycle.
  • The synergy limitation is central to both patentability and infringement analysis.
  • The patent is a treatment-method patent, not a broad neratinib composition or formulation patent.
  • The projected ordinary expiration is approximately January 2029, subject to official USPTO term adjustment.
  • The claimed metastatic combination is distinct from Nerlynx’s principal FDA-approved extended-adjuvant indication.
  • Orange Book relevance must be confirmed independently; the patent is not automatically an Orange Book barrier.
  • Generic risk is more likely to arise from neratinib composition, formulation, and approved-use patents than from this combination patent alone.
  • A label that omits the claimed combination may reduce induced-infringement exposure, but it does not resolve all patent risks.
  • No confirmed Paragraph IV challenge or settlement involving US 8,669,273 is established in this analysis.

FAQs

Does US Patent 8,669,273 cover neratinib monotherapy?

No. The independent claims require administration of both neratinib and capecitabine.

Does the patent cover trastuzumab and capecitabine combinations?

No. The claims identify neratinib and capecitabine. Trastuzumab-based regimens fall outside the literal combination claimed.

Can a competitor avoid claim 23 by changing the capecitabine schedule?

Potentially. A materially different schedule may avoid literal infringement, although the doctrine of equivalents and other patent claims would require separate analysis.

Is capecitabine’s generic availability enough to defeat the patent?

No. Generic availability of capecitabine does not invalidate a method patent covering its combination with neratinib.

Is this patent a biosimilar barrier?

No. Neratinib and capecitabine are small molecules. The relevant regulatory pathway is an ANDA or other small-molecule pathway, not a biosimilar application under the Biologics Price Competition and Innovation Act.

References

  1. United States Patent and Trademark Office. (2014). Methods for treating cancer using neratinib and capecitabine (U.S. Patent No. 8,669,273).

  2. U.S. Food and Drug Administration. (2017). Nerlynx (neratinib) prescribing information. Puma Biotechnology, Inc.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

  4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. Center for Drug Evaluation and Research.

  5. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation resources.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,669,273

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes 8,669,273 ⤷  Start Trial USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,669,273

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009279771 ⤷  Start Trial
Brazil PI0916694 ⤷  Start Trial
Canada 2730715 ⤷  Start Trial
China 102202667 ⤷  Start Trial
China 105147713 ⤷  Start Trial
China 105963313 ⤷  Start Trial
China 109464445 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.